Project
IDN-6556-14 NASH und Emricasan
Aborted ยท 2016 until 2021
Semela David, Alfter Christine
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Aborted
Start Date
2016
End Date
2021
Financing
Industry
Brief description/objective
A Multicenter, Randomized, Double-Blind, Placebo-
Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in
Subjects with Non-Alcoholic Steatohepatitis (NASH)
Cirrhosis and Severe Portal Hypertension